Microbicides for Preventing Transmission of Genital Herpes

Herpes

Volumn 9, Issue 1, 2002, Pages 4-9

  Zeitlin, Larry ^a   Whaley, Kevin J ^a  

^a Epicyte Pharmaceutical Inc   (United States)

Author keywords

Animal models; Genital herpes; Microbicides; Monoclonal antibodies; Mucosal protectant; Sexually transmitted infection; Transmission; Vertical transmission

Indexed keywords

ACIDFORM; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; BUFFER; CARBOPOL 974P; CARRAGEENAN; CD4 ANTIGEN; CD8 ANTIGEN; CELLULOSE SULFATE; CHEMOKINE; DETERGENT; EMMELLE; ESTRADIOL; HERPES SIMPLEX VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 1; MONOCLONAL ANTIBODY; NAPHTHALENE DERIVATIVE; NONOXINOL 9; PALIVIZUMAB; POLYCLONAL ANTIBODY; POLYMER; POLYSTYRENESULFONIC ACID; PRO 2000; PROTEIN ANTIBODY; PSS; SAVVY; SPERMICIDAL AGENT; SURFACTANT; UNCLASSIFIED DRUG; UNINDEXED DRUG; NONOXINOL;

ACIDITY; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CONDOM; CONTROLLED DRUG RELEASE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG SPECIFICITY; EXPERIMENTAL MODEL; GENITAL HERPES; HUMAN; LIPID MEMBRANE; MEDICAL TECHNOLOGY; NEWBORN INFECTION; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE; SULFATION; TECHNIQUE; VAGINITIS; VERTICAL TRANSMISSION; VIRUS CELL INTERACTION; VIRUS ENVELOPE; VIRUS REPLICATION; VIRUS TRANSMISSION; ANIMAL; ANIMAL MODEL; DISEASE TRANSMISSION; DRUG EFFECT; HERPES SIMPLEX VIRUS; INTRAVAGINAL DRUG ADMINISTRATION; SPECIES DIFFERENCE;

ANIMALIA;

ADMINISTRATION, INTRAVAGINAL; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; HERPES GENITALIS; HUMANS; MODELS, ANIMAL; NONOXYNOL; SIMPLEXVIRUS; SPECIES SPECIFICITY; SPERMATOCIDAL AGENTS;

EID: 0036550714     PISSN: 09697667     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Corey L, Langenberg AG, Ashley R, Sekulovich RE, Izu AE, Douglas JM, Jr et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 1999;282:331-340.
2. Spruance SL and the SmithKline Beecham Herpes Vaccine Efficacy Study Group. Gender-specific efficacy of a prophylactic SBAS4-adjuvant gD, subunit vaccine against genital herpes disease (GHD): results of two clinical efficacy trials (abstract). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000.
3. Population Council and International Family Health. The Case for Microbicides: a Global Priority (2000). New York: Population Council; and London: International Family Health, 2000.
4. Elias C, Heise L. Challenges for the development of female-controlled vaginal microbicides. AIDS 1994;8:1-9.
5. Cates W. Contraception, contraceptive technology, and STDs. In: Sexually Transmitted Diseases (Holmes K, Sparling P, Mardh PA, Lemon S, Stamm W, Piot P et al., eds). New York: McGraw-Hill 1999; pp1067-1078.
6. Whaley KJ, Barratt RA, Zeitlin L, Hoen TE, Cone RA. Nonoxynol-9 protects mice against vaginal transmission of genital herpes infections. J Infect Dis 1993;168:1009-1011.
7. Moench TR, Whaley KJ, Mandrell TD, Bishop BD, Witt CJ, Cone RA. The cat/feline immunodeficiency virus model for transmucosal transmission of AIDS: nonoxynol-9 contraceptive jelly blocks transmission by an infected cell inoculum. AIDS 1993;7:797-802.
8. Van Damme L. Advances in topical microbicides (oral). XIII World Conference on HIV/AIDS, Durban, South Africa, 2000.
9. Norvell MK, Benrubi GI, Thompson RJ. Investigation of microtrauma after sexual intercourse. J Reprod Med 1984;29:269-271.
10. Phillips DM, Zacharopoulos VR. Nonoxynol-9 enhances rectal infection by herpes simplex virus in mice. Contraception 1998;57:341-348.
11. Achilles S, Shete P, Moench T, Cone R. Evaluating acute in vivo toxicity of microbicides on genital tract epithelium. Int J STD AIDS 2001;12(Suppl 2):35.
12. Patton D, Cosgrove Sweeney Y, Rabe L, Hillier S. Effects of multiple applications of nonoxynol-9 on rectal tissues and microflora in a monkey model. Int J STD AIDS 2001;12(Suppl 2):35.
13. Phillips DM, Taylor CL, Zacharopoulos VR, Maguire RA. Nonoxynol-9 causes rapid exfoliation of sheets of rectal epithelium. Contraception 2000;62:149-154.
14. Fichorova RN, Tucker LD, Anderson DJ. The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J Infect Dis 2001;184:418-428.
15. Miller CJ, Alexander NJ, Sutjipto S, Joye SM, Hendrickx AG, Jennings M et al. Effect of virus dose and nonoxynol-9 on the genital transmission of SIV in rhesus macaques. J Med Primatol 1990;19:401-409.
16. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000;6:207-210.
17. Burkhard MJ, Obert LA, O'Neil LL, Diehl LJ, Hoover EA. Mucosal transmission of cell-associated and cell-free feline immunodeficiency virus. AIDS Res Hum Retroviruses 1997;13:347-355.
18. Jerse AE. Experimental gonococcal genital tract infection and opacity protein expression in estradioltreated mice. Infect Immun 1999;67:5699-5708.
19. Burillo CA, Fontenot JD, Phillips DM. Sulfated polysaccharides block chlamydia infection in vitro, but do not protect mice from vaginal inoculation. Microb Pathog 1998;24:253-256.
20. Lyons J, Ito J. Reducing the risk of Chlamydia trachomatis genital tract infection by evaluating the prophylactic potential of vaginally applied chemicals. Clin Infect Dis 1995;21(Suppl 2):S174-S177.
21. Christensen ND, Reed CA, Cladel NM, Han R, Kreider JW. Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 1996;70:960-965.
22. Bonnez W, DaRin C, Borkhuis C, de Mesy Jensen K, Reichman RC, Rose RC. Isolation and propagation of human papillomavirus type 16 in human xenografts implanted in the severe combined immunodeficiency mouse. J Virol 1998;72:5256-5261.
23. Bourne N, Ireland J, Stanberry LR, Bernstein DI. Effect of undecylenic acid as a topical microbicide against genital herpes infection in mice and guinea pigs. Antiviral Res 1999;40:139-144.
24. Zeitlin L, Whaley KJ, Hegarty TA, Moench TR, Cone RA. Tests of vaginal microbicides in the mouse genital herpes model. Contraception 1997;56:329-335.
25. Zeitlin L, Hoen TE, Achilles SL, Hegarty TA, Jerse AE, Kreider JW et al. Tests of Buffergel for contraception and prevention of sexually transmitted diseases in animal models. Sex Transm Dis 2001;28:417-423.
26. Points to Consider in the Nonclinical Pharmacology/Toxicology Development of Topical Drugs Intended to Prevent the Transmission of Sexually Transmitted Diseases (STD) and/or for the Development of Drugs Intended to Act as Vaginal Contraceptives. US Food and Drug Administration. Center for Drug Evaluation and Research. Guidance Documents. Available at: www.fda.gov/cder/guidance/ptcnonclinical.htm
27. Maguire RA, Bergman N, Phillips DM. Comparison of microbicides for efficacy in protecting mice against vaginal challenge with herpes simplex virus type 2, cytotoxicity, antibacterial properties, and sperm immobilization. Sex Transm Dis 2001;28:259-265.
28. Eng T, Butler W (eds). The Hidden Epidemic. Washington, DC: National Academy Press, 1997.
29. Alliance for Microbicide Development. Available at: www.microbicide.com
30. Cone RA, Whaley KJ. Monoclonal antibodies for reproductive health: Part I. Preventing sexual transmission of disease and pregnancy with topically applied antibodies. Am J Reprod Immunol 1994;32:114-131.
31. Zeitlin L, Cone RA, Whaley KJ. Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases. Emerg Infect Dis 1999;5:54-64.
32. Whaley K, Zeitlin L. Antibodies as mucosal protectants (in French). Annales de l'Institut Pasteur/actualites 2001;7:83-100.
33. Kraehenbuhl JP, Neutra MR. Molecular and cellular basis of immune protection of mucosal surfaces. Physiol Rev 1992;72:853-879.
34. Baez J, Russell D, Craig J. Corn seed production of therapeutic proteins moves forward. Biopharm, August 2000. Eugene, OR: Advanstar Communications, 2000; pp50-54.
35. Moench T, Blumenthal P, Cone R, Whaley K. Antibodies may provide prolonged microbicidal activity due to their long residence time in the vagina (abstract). Microbicides 2000. Alexandria, VA, 2000.
36. Dix RD, Pereira L, Baringer JR. Use of monoclonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease. Infect Immun 1981;34:192-199.
37. Balachandran N, Bacchetti S, Rawls WE. Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2. Infect Immun 1982;37:1132-1137.
38. Eis-Hübinger A, Schmidt D, Schneweis K. Anti-glycoprotein B monoclonal antibody protects mice against genital herpes simplex virus infection by inhibition of virus replication at the inoculated mucous membranes. J Gen Virol 1993;74:379-385.
39. Whaley KJ, Zeitlin L, Barratt RA, Hoen TE, Cone RA. Passive immunization of the vagina protects mice against vaginal transmission of genital herpes infections. J Infect Dis 1994;169:647-649.
40. Zeitlin L, Whaley KJ, Sanna PP, Moench TR, Bastidas R, De Logu A et al. Topically applied human recombinant monoclonal lgG1 antibody and its Fab and F(ab')2 fragments protect mice from vaginal transmission of HSV-2. Virology 1996;225:213-215.
41. Radomsky ML, Whaley KJ, Cone RA, Saltzman WM. Controlled vaginal delivery of antibodies in the mouse. Biol Reprod 1992;47:133-140.
42. Saltzman WM, Sherwood JK, Adams DR, Haller P. Long-term vaginal antibody delivery: delivery systems and biodistribution. Biotechnol Bioeng 2000;67:253-264.
43. Sherwood J, Zeitlin L, Whaley K, Cone R, Saltzman W. Controlled release of antibodies for long-term topical passive immunoprotection of female mice against genital herpes. Nat Biotechnol 1996;14:468-471.
44. Cassone A, Boccanera M, Adriani D, Santoni G, De Bernardis F. Rats clearing a vaginal infection by Candida albicans acquire specific, antibody-mediated resistance to vaginal reinfection. Infect Immun 1995;63:2619-2624.
45. Peterson EM, Cheng X, Motin VL, de la Maza LM. Effect of immunoglobulin G isotype on the infectivity of Chlamydia trachomatis in a mouse model of intravaginal infection. Infect Immun 1997;65:2693-2699.
46. Achilles S. Microbicides for Blocking Vaginal Transmission of Chlamydia: Efficacy and Mechanisms of Action (doctoral dissertation). The Johns Hopkins University, Baltimore, USA, 2000.
47. Christensen ND, Kreider JW. Antibody-mediated neutralization in vivo of infectious papillomaviruses. J Virol 1990;64:3151-3156.
48. Ma JK, Hikmat BY, Wycoff K, Vine ND, Chargelegue D, Yu L et al. Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans. Nat Med 1998;4:601-606.
49. Burman LG, Christensen P, Christensen K, Fryklund B, Helgesson AM, Svenningsen NW et al. Prevention of excess neonatal morbidity associated with group B streptococci by vaginal chlorhexidine disinfection during labour. The Swedish Chlorhexidine Study Group. Lancet 1992;340:65-69.
50. Gaillard P, Mwanyumba F, Verhofstede C, Claeys P, Chohan V, Goetghebeur E et al. Vaginal lavage with chlorhexidine during labour to reduce mother-to-child HIV transmission: clinical trial in Mombasa, Kenya. AIDS 2001;15:389-396.
51. Klein J, Remington J (eds). Infectious Diseases of the Fetus and Newborn Infant. Philadelphia: WB Saunders Company, 2001;pp1-23.
52. Ashley RL, Dalessio J, Burchett S, Brown Z, Berry S, Mohan K et al. Herpes simplex virus-2 (HSV-2) type-specific antibody correlates of protection in infants exposed to HSV-2 at birth. J Clin Invest 1992;90:511-514.
53. Whitley RJ. Neonatal herpes simplex virus infections: is there a role for immunoglobulin in disease prevention and therapy? Pediatr Infect Dis J 1994;13:432-438; Discussion 438-439.
54. Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD, Jr. Acyclovir suppression to prevent clinical recurrences at delivery after first episode genital herpes in pregnancy: an open-label trial. Infect Dis Obstet Gynecol 2001;9:75-80.
55. Bernstein DI, Loo LS, Kohl S. Antibody to cloned HSV glycoproteins B and D plus adult human leukocytes protect neonatal mice from lethal HSV infection. Antiviral Res 1988;10:279-287.
56. Bravo FJ, Bourne N, Harrison CJ, Mani C, Stanberry LR, Myers MG et al. Effect of antibody alone and combined with acyclovir on neonatal herpes simplex virus infection in guinea pigs. J Infect Dis 1996;173:1-6.
57. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000;6:200-206.
58. Singh M, Sugathan PS, Bhujwala RA. Human colostrum for prophylaxis against sticky eyes and conjunctivitis in the newborn. J Trop Pediatr 1982;28:35-37.
59. Herold BC, Bourne N, Marcellino D, Kirkpatrick R, Strauss DM, Zaneveld LJ et al. Poly(sodium 4-styrene sulfonate): an effective candidate topical antimicrobial for the prevention of sexually transmitted diseases. J Infect Dis 2000;181:770-773.
60. Zeitlin L, Castle P, Whaley K, Moench T, Cone R. Comparison of an anti-HSV-2 monoclonal IgG and its IgA switch variant for topical immunoprotection of the mouse vagina. J Reprod Immunol 1998;40:93-101.
61. Zeitlin L, Olmsted SS, Moench TR, Co MS, Martinell BJ, Paradkar VM et al. A humanized monoclonal antibody produced in transgenic plants for immunoprotection of the vagina against genital herpes. Nat Biotechnol 1998;16:1361-1364.
62. Briggs K, Zeitlin L, Wang F, Chen L, Fitchen J, Glynn J et al. An anti-HSV antibody produced in transgenic rice plants prevents vaginal HSV-2 infection in mice (abstract). Microbicides 2000, Alexandria, VA, 2000.